ReviewFrontiers in oncology2026
The validity of the AEON™ stapler in gastrointestinal surgery: early clinical experience and translational rationale.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/need: Gastrointestinal stapling continues to be limited by bleeding, variable compression and leak-related morbidity, especially in bariatric and hepatopancreatobiliary (HPB) surgery. The AEON™ stapler was developed to improve uniformity of compression and staple formation. Methodology and device description: AEON™ uses an S3 (sustained, smooth and stable) compression mechanism to reduce tissue shear and optimise B-shaped staple formation. Evidence comes from a randomised controlled trial in sleeve gastrectomy, a large bariatric cohort and observational HPB series. Preliminary results: Across 1, 848 bariatric cases, only one staple-line leak occurred, and 428 consecutive AEON™ cases had no stapler-related complications. A sleeve gastrectomy trial showed significantly reduced intraoperative bleeding. In a 250-patient comparison, reinforcement was required in 16.8% of AEON™ cases versus 100% using a tri-staple device. Distal pancreatectomy with AEON™ showed a pancreatic fistula rate of 20% compared with 65% for traditional staplers, and major hepatectomy was completed without transfusion in any AEON™ case. Current status: AEON™ is in active clinical use with early results supporting improved haemostasis and postoperative outcomes. Larger prospective studies are underway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.